Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04129086
Other study ID # HSC-MS-19-0726
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 1, 2020
Est. completion date September 30, 2022

Study information

Verified date March 2023
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness of Ketamine drip along with usual care and usual care alone on trauma patients and to longitudinally quantify the pain experience of patients during hospitalization.


Recruitment information / eligibility

Status Completed
Enrollment 305
Est. completion date September 30, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: - Adult trauma patients - Admission to Shock Trauma ICU (STICU) or Surgical Intermediate Unit (SIMU) - Randomization within 6 hours of arrival Exclusion Criteria: - Patient not expected to survive - Contraindications to ketamine Allergy, Poorly controlled hypertension, Cardiac arrhythmia disorders (including atrial fibrillation), congestive heart failure, unstable coronary artery disease or recent myocardial infarction( MI)(within 6 months), cirrhosis, seizure disorder, and for those patients with unknown medical history - median sternotomy scar, mechanism of injury is fall from standing, 65 years of age or older, any arrhythmia on EKD) - pregnancy - in police custody - history of dementia or movement disorder (i.e. Parkinson's)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine plus usual care
Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
Usual Care
Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.

Locations

Country Name City State
United States The University of Texas Health Science Center at Houston Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average Daily Opioid Use as Measured by the Morphine Milligram Equivalents (MME) Per Day In-hospital days (up to 6 weeks post hospital admission)
Secondary Pain as Assessed by Score on the Numeric Rating Scale (NRS) The NRS ranges from 0 (no pain) to 10 (worst pain), with a higher score indicating a worse outcome. This scale is used in verbal participants. Hospital discharge (up to 6 weeks post hospital admission)
Secondary Number of Patients That Showed Signs of Delirium During In-hospital Stay Incidence of delirium during in-hospital stay Hospital discharge (up to 6 weeks post hospital admission)
Secondary Number of Patients That Required Unplanned Intubation During In-hospital Stay incidence of need for unplanned intubation during in-hospital stay Hospital discharge (up to 6 weeks post hospital admission)
Secondary Number of Patients Who Required Unplanned Admission to Intensive Care Unit During In-hospital Stay Incidence of need for unplanned admission to an ICU Hospital discharge (up to 6 weeks post hospital admission)
Secondary Initiation of Ketamine Drip Time from admission to time Ketamine drip started Hospital discharge (up to 6 weeks post hospital admission)
Secondary Duration of Ketamine Drip Length of time Ketamine drip was infused Hospital discharge (up to 6 weeks post hospital admission)
Secondary Number of Patients Requesting to Discontinue Ketamine Number of patients requesting to stop Ketamine for any complaint Hospital discharge (up to 6 weeks post hospital admission)
Secondary Use of Other Pain Control Adjuncts Including Regional Anesthesia and Lidocaine Patch Incidence of use of additional pain control adjuncts such as regional anesthesia and lidocaine patch during hospitalization Hospital discharge (up to 6 weeks post hospital admission)
Secondary Ventilator Free Days Number of inpatient hospital days patients did not require mechanical ventilation Hospital discharge (up to 6 weeks post hospital admission)
Secondary ICU Free Days Number of inpatient hospital days patients did not require ICU level of care Hospital discharge (up to 6 weeks post hospital admission)
Secondary Hospital Free Days Number of days patients were not in the hospital during the first 30 days after admission 30 days post admission
Secondary Number of Patients Discharged From the Hospital With an Opioid Prescription Number of patients discharged from the hospital with an opioid prescription Hospital discharge (up to 6 weeks post hospital admission)
Secondary Number of Patients Who Reported Continued Pain Continued Post-traumatic Pain at 6 Months Post Admission Number of patients who reported continued pain at 6 months following trauma injury 6 months post admission
Secondary Number of Patients Who Continue to Use Opioids at 6 Months Post Admission Number of patients who continue to use opioids 6 months post admission
Secondary Post Traumatic Stress Disorder (PTSD) as Assessed by the PC-PTSD-5 Questionnaire The PC-PTSD-5 questionnaire asks the below 5 questions, and data are reported categorically as the number of participants who responded "yes" to each of the 5 questions. An answer of "yes" is indicative of a PTSD symptom, which is a worse outcome.
In the past month, have you had nightmares about the events or thought about the events when you did not want to?
In the past month, have you tried hard not to think about the events or went out of your way to avoid situations that reminded you of the events?
In the past month, have you been constantly on guard, watchful, or easily startled?
In the past month, have you felt numb or detached from people, activities, or your surroundings?
In the past month, have you felt guilty or unable to stop blaming yourself or others for the events or any problems the events may have caused?
6 months post admission
Secondary Risk of Future Opioid Abuse as Assessed by the Opioid Risk Tool (ORT) Total ORT score ranges from 0 to 26. A score of 3 or lower indicates low risk for future opioid abuse, a score of 4 to 7 indicates moderate risk for opioid abuse, and a score of 8 or higher indicates a high risk for opioid abuse. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Mobility) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of mobility by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Self-Care) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of self-care by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Usual Activities) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their ability to carry out usual activities by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Pain/Discomfort) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of pain/discomfort by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Anxiety/Depression) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of anxiety/depression by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Current Health) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked the question "How would you rate your health today?," and they respond with a score from 0 - 100, with a higher score indicating a better outcome. Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Previous Experience) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked the question "Have you ever experience this kind of event?," and data are reported as the number of participants who responded "yes." Hospital discharge (about 1 to 6 weeks after admission)
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Mobility) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of mobility by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. 6 months post admission
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Self-Care) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of mobility by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. 6 months post admission
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Usual Activities) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their ability to carry out usual activities by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. 6 months post admission
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Pain/Discomfort) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of pain/discomfort by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. 6 months post admission
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Anxiety/Depression) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked to indicate their level of anxiety/depression by choosing a predefined category, and the data for this outcome are reported categorically as the number of participants who chose each category. 6 months post admission
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Current Health) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked the question "How would you rate your health today?," and they respond with a score from 0 - 100, with a higher score indicating a better outcome. 6 months post admission
Secondary Health Status as Assessed by the Euro-QOL EQ-5D-3L Questionnaire (Previous Experience) For this item of the Euro-QOL EQ-5D-3L questionnaire, participants are asked the question "Have you ever experience this kind of event?," and data are reported as the number of participants who responded "yes." 6 months post admission
Secondary Post Traumatic Stress Disorder (PTSD) as Assessed by the PC-PTSD-5 Questionnaire The PC-PTSD-5 questionnaire asks the below 5 questions, and data are reported categorically as the number of participants who responded "yes" to each of the 5 questions. An answer of "yes" is indicative of a PTSD symptom, which is a worse outcome.
In the past month, have you had nightmares about the events or thought about the events when you did not want to?
In the past month, have you tried hard not to think about the events or went out of your way to avoid situations that reminded you of the events?
In the past month, have you been constantly on guard, watchful, or easily startled?
In the past month, have you felt numb or detached from people, activities, or your surroundings?
In the past month, have you felt guilty or unable to stop blaming yourself or others for the events or any problems the events may have caused?
Hospital discharge (about 1 to 6 weeks after admission)
Secondary Pain as Assessed by Score on the Behavioral Pain Scale (BPS) BPS score ranges from 3-12, with higher scores indicating worse pain. This assessment is used in non-verbal participants. Hospital discharge (up to 6 weeks post hospital admission)
Secondary Pain as Assessed by Average Score on the Defense and Veterans Pain Rating Scale (DVPRS) DVPRS scores were collected daily. For each participant, an average of the daily scores on the Defense and Veterans Pain Rating Scale was calculated. DVPRS scores range from 0 (no pain) to 10 (as bad as it could be, nothing else matters), with a higher score indicating a worse outcome. From time of admission to time of discharge from hospital (about 1 to 6 weeks after admission)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Completed NCT04748367 - Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care N/A
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04466111 - Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05868122 - A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy Phase 3
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Completed NCT03273114 - Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain N/A
Enrolling by invitation NCT06087432 - Is PNF Application Effective on Temporomandibular Dysfunction N/A
Completed NCT05508594 - Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 Phase 2/Phase 3
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Active, not recruiting NCT03472300 - Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
Completed NCT03678168 - A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries N/A
Completed NCT03286543 - Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System N/A
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02913027 - Can We Improve the Comfort of Pelvic Exams? N/A
Terminated NCT02181387 - Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor? Phase 4
Recruiting NCT06032559 - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment Phase 3
Active, not recruiting NCT03613155 - Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care